Depending on the local expertise and availability of laboratory equipment, different methods may permit adequate surveillance of BCR-ABL1 TKD mutations relevant in the context of TKI resistance as a basis for optimal management of patients with Ph-positive leukemias. This evidence concerns the gene ABL1 and leukemia.